What is claimed is:

Claim 1. A method of detecting preeclampsia and/or determining an increased risk for preeclampsia in a pregnant female, the method comprising:

identifying in a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules;

wherein the identification of a plurality of C-RNA molecules is selected from:

(a) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, or all of arrestin domain containing 2 (ARRDC2), Jun proto-oncogene, AP-1 transcription factor subunit (JUN), ski like proto-oncogene (SKIL), ATPase 13A3 (ATP13A3), phosphodiesterase 8B (PDE8B), glutathione S-transferase alpha 3 (GSTA3), TCDD inducible poly (ADP-ribose) polymerase (TIPARP), RGP1 homolog, RAB6A GEF complex partner 1 (RGP1), ubiquitin specific peptidase 54 (USP54), C-type lectin domain family 4 member C (CLEC4C), mitochondrial ribosomal protein S35 (MRPS35), Rho guanine nucleotide exchange factor 25 (ARHGEF25), cut like homeobox 2 (CUX2), HEAT repeat containing 9 (HEATR9), follistatin like 3 (FSTL3), DNA damage inducible 1 homolog 2 (DDI2), zinc finger MYM-type containing 6 (ZMYM6), ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 (ST6GALNAC3), guanylate binding protein 2 (GBP2), ETS variant 3 (ETV3), ADAM metallopeptidase domain 17 (ADAM17), atonal bHLH transcription factor 8 (ATOH8), solute carrier family 4 member 3 (SLC4A3), TRAF3 interacting protein 1 (TRAF3IP1),

tetratricopeptide repeat domain 21A (TTC21A), heart development protein with EGF like domains 1 (HEG1), asteroid homolog 1 (ASTE1), transmembrane protein 108 (TMEM108), ectodermal-neural cortex 1 (ENC1), secretory carrier membrane protein 1 (SCAMP1), arrestin domain containing 3 (ARRDC3), solute carrier family 26 member 2 (SLC26A2), slit guidance ligand 3 (SLIT3), chloride intracellular channel 5 (CLIC5), TNF receptor superfamily member 21 (TNFRSF21), protein phosphatase 1 regulatory subunit 17 (PPP1R17), tyrosylprotein sulfotransferase 1 (TPST1), cytosolic arginine sensor for mTORC1 subunit 2 (GATSL2), speedy/RINGO cell cycle regulator family member E5 (SPDYE5), homeodomain interacting protein kinase 2 (HIPK2), MT-RNR2 like 6 (MTRNR2L6), chloride voltage-gated channel 1 (CLCN1), GINS complex subunit 4 (GINS4), twinkle mtDNA helicase (C10orf2), TruB pseudouridine synthase family member 1 (TRUB1), aminoacylase 3 (ACY3), fatty acyl-CoA reductase 2 (FAR2), CD63 molecule (CD63), cytoskeleton associated protein 4 (CKAP4), two pore segment channel 1 (TPCN1), ring finger protein 6 (RNF6), thiamine triphosphatase (THTPA), Fos proto-oncogene, AP-1 transcription factor subunit (FOS), poly(A)-specific ribonuclease (PARN), ORAI calcium release-activated calcium modulator 3 (ORAI3), engulfment and cell motility 3 (ELMO3), sphingomyelin phosphodiesterase 3 (SMPD3), serpin family F member 1 (SERPINF1), transmembrane protein 11 (TMEM11), proteasome 26S subunit, non-ATPase 11 (PSMD11), C-type lectin domain family 4 member M (CLEC4M), coiled-coil domain containing 151 (CCDC151), C3 and PZP like alpha-2-macroglobulin domain containing 8 (CPAMD8), cornifelin (CNFN), eukocyte immunoglobulin like receptor A4 (LILRA4), adenosine deaminase (ADA), chromosome 22 open reading frame 39 (C22orf39), phosphatidylinositol 4-kinase alpha pseudogene 1 (PI4KAP1), and ADP ribosylation factor GTPase activating protein 3 (ARFGAP3); or

(b) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of TIMP metallopeptidase inhibitor 4 (TIMP4), filaggrin (FLG), HtrA serine peptidase 4 (HTRA4), amphiphysin (AMPH), lipocalin 6 (LCN6), TEA domain transcription factor 4 (TEAD4), age-related maculopathy susceptibility 2 (ARMS2), semaphorin 3G (SEMA3G), ADAM metallopeptidase with thrombospondin type 1 motif 1 (ADAMTS1), arachidonate 15-lipoxygenase type B (ALOX15B), SLC9A3 regulator 2 (SLC9A3R2), insulin like growth factor binding protein 5 (IGFBP5), heat shock protein family A (Hsp70) member 12B (HSPA12B), C-type lectin domain family 4 member C (CLEC4C), keratin 5 (KRT5), periaxin (PRX), Rho guanine nucleotide exchange factor 25 (ARHGEF25), α disintegrin and metallopeptidase with thrombospondin type 1 motif 2 (ADAMTS2), dishevelled associated activator of morphogenesis 2 (DAAM2), and family with sequence similarity 107 member A (FAM107A); or

(c) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, any seventy-five or more, any one hundred or more, or all of cytochrome P450 family 26 subfamily B member 1 (CYP26B1), interferon regulatory factor 6 (IRF6), myosin heavy chain 14 (MYH14), podocalyxin like (PODXL), protein phosphatase 1 regulatory subunit 3C (PPP1R3C), SH3 domain containing ring finger 2 (SH3RF2), transmembrane channel like 7 (TMC7), zinc finger protein 366

(ZNF366), adenylate cyclase 1 (ADCY1), complement C6 (C6), family with sequence similarity 219 member A (FAM219A), hydroxyacid oxidase 2 (HAO2), IgA inducing protein (IGIP), interleukin 1 receptor type 2 (IL1R2), neurotrophic receptor tyrosine kinase 2 (NTRK2), SH3 and PX domains 2A (SH3PXD2A), ssu-2 homolog (SSUH2), sulfotransferase family 2A member 1 (SULT2A1), flavin containing dimethylaniline monoxygenase 3 (FMO3), follistatin like 3 (FSTL3), GATA binding protein 5 (GATA5), HtrA serine peptidase 1 (HTRA1), complement C8 beta chain (C8B), MN1 proto-oncogene, transcriptional regulator (MN1), nuclear factor, erythroid 2 like 1 (NFE2L1), PR/SET domain 16 (PRDM16), adaptor related protein complex 3 subunit beta 2 (AP3B2), epithelial membrane protein 1 (EMP1), filamin C (FLNC), stromal antigen 3 (STAG3), carboxypeptidase B2 (CPB2), tensin 2 (TENC1), RP1 like 1 (RP1L1), APOBEC1 complementation factor (A1CF), natriuretic peptide receptor 1 (NPR1), TEK receptor tyrosine kinase (TEK), ERBB receptor feedback inhibitor 1 (ERRFI1), Rho guanine nucleotide exchange factor 15 (ARHGEF15), CD34 molecule (CD34), R-spondin 3 (RSPO3), alpha kinase 3 (ALPK3), sterile alpha motif domain containing 4A (SAMD4A), zinc finger CCHC-type containing 24 (ZCCHC24), liver enriched antimicrobial peptide 2 (LEAP2), myosin light chain 2 (MYL2), neuregulin 3 (NRG3), zinc finger and BTB domain containing 16 (ZBTB16), serpin family A member 3 (SERPINA3), aquaporin 7 (AQP7), sushi repeat containing protein X-linked (SRPX), uveal autoantigen with coiled-coil domains and ankyrin repeats (UACA), anoctamin 1 (ANO1), FKBP prolyl isomerase 5 (FKBP5), sodium voltage-gated channel alpha subunit 5 (SCN5A), protein tyrosine phosphatase non-receptor type 21 (PTPN21), calcium voltage-gated channel subunit alpha1 C (CACNA1C), ETS transcription factor ERG (ERG), SRY-box 17 (SOX17), WW domain containing transcription regulator 1 (WWTR1), allograft inflammatory factor 1 like (AIF1L), carbonic anhydrase 3 (CA3), histidine rich glycoprotein (HRG), tyrosine aminotransferase (TAT), aquaporin 7 pseudogene 1 (AQP7P1), adrenoceptor alpha 2C (ADRA2C), synaptopodin (SYNPO), adhesion G protein-coupled receptor F5 (GPR116), keratin 17 (KRT17), alpha-2-glycoprotein 1, zinc-binding (AZGP1), BCL6B

transcription repressor (BCL6B), kinesin family member 1C (KIF1C), chloride intracellular channel 5 (CLIC5), G protein-coupled receptor 4 (GPR4), gap junction protein alpha 5 (GJA5), oleoyl-ACP hydrolase (OLAH), armadillo like helical domain containing 4 (C14orf37), zinc finger E-box binding homeobox 1 (ZEB1), jagged canonical Notch ligand 2 (JAG2), kinesin family member 26A (KIF26A), apolipoprotein L domain containing 1 (APOLD1), phenylethanolamine N-methyltransferase (PNMT), myomesin 3 (MYOM3), PITPNM family member 3 (PITPNM3), TIMP4, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, hemoglobin subunit gamma 2 (HBG2), cell adhesion molecule 2 (CADM2), lysosomal associated membrane protein family member 5 (LAMP5), prostaglandin D2 receptor 2 (PTGDR2), NODAL modulator 1 (NOMO1), nuclear RNA export factor 3 (NXF3), phospholipase D family member 4 (PLD4), BPIFB3, protein kinase C and casein kinase substrate in neurons 1 (PACSIN1), CUX2, FLG, CLEC4C, and KRT5; or

(d) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or all twenty-three of ADAMTS2, FAM107A, DAAM2, ARHGEF25, , PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, TEAD4, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4; or

(e) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more,

any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, or all twenty-one of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CUGBP Elav-like family member 4 (CELF4), DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, potassium voltage-gated channel subfamily A member 5 (KCNA5), KRT5, LCN6, leucine rich repeat containing 26 (LRRC26), OLAH, PACSIN1, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(f) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or all of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(g) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, or all six of CLEC4C, ARHGEF25, ADAMTS2, ARRDC2, SKIL, and arrestin domain containing 4 (ARRDC4); or

(h) a plurality of C-RNA molecules encoding a coding region of a protein selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or all twenty of KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, ACY3, PLD4, secretin (SCT), NADPH oxidase 4 (NOX4), PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, phosphate regulating endopeptidase homolog X-linked (PHEX), LILRA4, and period circadian regulator 1 (PER1), is indicative of preeclampsia and/or an increased risk for preeclampsia in the pregnant women.

Claim 2. A method of detecting preeclampsia and/or determining an increased risk for preeclampsia in a pregnant female, the method comprising:

purifying a population of circulating RNA (C-RNA) molecules from a biosample obtained from the pregnant female;

identifying protein coding sequences encoded by the C-RNA molecules within the purified population of C-RNA molecules;

wherein the identification of protein coding sequences encoded by the C-RNA molecules encoding a coding region of a protein selected from:

(a) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, or all of ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, TIPARP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, C10orf2, TRUB1, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3; or

(b) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of TIMP4, FLG, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1,

ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, CLEC4C, KRT5, PRX, ARHGEF25, ADAMTS2, DAAM2, and FAM107A; or

(c) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, any seventy-five or more, any one hundred or more, or all of CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5; or

(d) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, or all twenty-three of

ADAMTS2, FAM107A, DAAM2, ARHGEF25, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, TEAD4, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4; or

(e) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, or all twenty-one of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PACSIN1, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, or all seventeen of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(g) any one or more, any two or more, any three or more, any four or more, any five or more, or all six of CLEC4C, ARHGEF25, ADAMTS2, ARRDC2, SKIL, and ARRDC4; or

(h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1,

is indicative of preeclampsia and/or an increased risk for preeclampsia in the pregnant women.

Claim 3. The method of claim 2, wherein identifying the plurality of C-RNA molecules or identifying protein coding sequences encoded by C-RNA molecules within the biosample comprises hybridization, reverse transcriptase PCR, microarray chip analysis, or sequencing.

Claim 4. The method of claim 3, wherein sequencing comprises:

a) massively parallel sequencing of clonally amplified molecules; or

b) RNA sequencing.

Claim 5. The method of claim any one of claims 1 to 4, further comprising:

removing intact cells from the biosample;

treating the biosample with a deoxynuclease (DNase) to remove cell free DNA (cfDNA);

synthesizing complementary DNA (cDNA) from C-RNA molecules in the biosample; and/or

enriching the cDNA sequences for DNA sequences that encode proteins by exome enrichment;

prior to identifying protein coding sequence encoded by the circulating RNA (C-RNA) molecules.

Claim 6. A method of detecting preeclampsia and/or determining an increased risk for preeclampsia in a pregnant female, the method comprising:

removing intact cells from a biosample obtained from the pregnant female;

treating the biosample with a deoxynuclease (DNase) to remove cell free DNA (cfDNA);

synthesizing complementary DNA (cDNA) from RNA molecules in the biosample;

enriching the cDNA sequences for DNA sequences that encode proteins (exome enrichment);

sequencing the resulting enriched cDNA sequences; and

identifying protein coding sequences encoded by enriched C-RNA molecules;

wherein the identification of protein coding sequences encoded by the C-RNA molecules encoding a coding region of a protein selected from**:**

(a) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, or all of ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, TIPARP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, C10orf2, TRUB1, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3; or

(b) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of TIMP4, FLG, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, CLEC4C, KRT5, PRX, ARHGEF25, ADAMTS2, DAAM2, and FAM107A; or

(c) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or

more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, any seventy-five or more, any one hundred or more, or all of CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5; or

(d) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, or all twenty-three of ADAMTS2, FAM107A, DAAM2, ARHGEF25, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, TEAD4, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4; or

(e) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or

more, or all twenty-one of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PACSIN1, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, or all eighteen of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(g) any one or more, any two or more, any three or more, any four or more, any five or more, or all six of CLEC4C, ARHGEF25, ADAMTS2, ARRDC2, SKIL, and ARRDC4; or

(h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1,

is indicative of preeclampsia and/or an increased risk for preeclampsia in the pregnant women.

Claim 7. A method comprising:

removing intact cells from a biosample obtained from the pregnant female;

treating the biosample with a deoxynuclease (DNase) to remove cell free DNA (cfDNA);

synthesizing complementary DNA (cDNA) from RNA molecules in the biosample;

enriching the cDNA sequences for DNA sequences that encode proteins (exome enrichment);

sequencing the resulting enriched cDNA sequences; and

identifying protein coding sequences encoded by the enriched C-RNA molecules;

wherein protein coding sequences encoded by the C-RNA molecules includes a coding region of a protein are selected from**:**

(a) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, or all seventy of ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3TIPARP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, C10orf2, TRUB1, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3; or

(b) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of TIMP4, FLG, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, CLEC4C, KRT5, PRX, ARHGEF25, ADAMTS2, DAAM2, and FAM107A;

(c) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine

or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, any seventy-five or more, any one hundred or more, or all of CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5; or

(d) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, or all twenty-three of ADAMTS2, FAM107A, DAAM2, ARHGEF25, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, TEAD4, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4; or

(e) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine

or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, or all twenty-one of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, , LRRC26, OLAH, PACSIN1, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, or all eighteen of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PRX, PTGDR2, SEMA3G, and SLC9A3R2; or

(g) any one or more, any two or more, any three or more, any four or more, any five or more, or all six of CLEC4C, ARHGEF25, ADAMTS2, ARRDC2, SKIL, and ARRDC4; or

(h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1.

Claim 8. The method of any one of claims 1 to 7, wherein the biosample comprises plasma and/ or, wherein the biosample is obtained from a pregnant female: at less than 16 weeks gestation; at less than 20 weeks gestation; or at greater than 20 weeks gestation.

Claim 9. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty one or more, any twenty two or more, any twenty three or more, any twenty four or more, any twenty five or more, any fifty or more, or all seventy of ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, TIPARP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, C10orf2, TRUB1, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3.

Claim 10. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of TIMP4, FLG, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, CLEC4C, KRT5, PRX, ARHGEF25, ADAMTS2, DAAM2, and FAM107A,.

Claim 11. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising a plurality of CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3,

ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, TEAD4, ARMS2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, IGFBP5, HSPA12B, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5.

Claim 12. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, or all twenty-three of ADAMTS2, FAM107A, DAAM2, ARHGEF25, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, TEAD4, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4.

Claim 13. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, or all twenty-one of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PACSIN1, PRX, PTGDR2, SEMA3G, and SLC9A3R2.

Claim 14. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more,

any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, or all eighteen of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LRRC26, OLAH, PRX, PTGDR2, SEMA3G, and SLC9A3R2.

Claim 15. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, or all six of CLEC4C, ARHGEF25, ADAMTS2, ARRDC2, SKIL, ARRDC4.

Claim 16. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, wherein the C-RNA signature consists of:

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, leptin (LEP), pappalysin 2 (PAPPA2), and V-set and immunoglobulin domain containing 4 (VSIG4);

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, and VSIG4;

ADAMTS2, ARHGEF25, arrestin domain containing 4 (ARRDC4), CLEC4C, LEP, nestin (NES), SKIL, and VSIG4;

ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, corticotropin releasing hormone (CRH, LEP), PAPPA2, SKIL, and VSIG4;

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or

ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL.

Claim 17. A circulating RNA (C-RNA) signature for an increased risk of preeclampsia, the C-RNA signature comprising any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, or all twenty of KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1.

Claim 18. A solid support array comprising a plurality of agents complementary to and capable of binding a C-RNA signature of any one of claims 9 to 17.

Claim 19. A kit comprising a plurality of probes capable of binding and/or identifying a C-RNA signature of any one of claims 9 to 17.

Claim 20. A kit comprising a plurality of primers for selectively amplifying a C-RNA signature of any one of claims 9 to 17.

Claim 21. The method of any one of claims 1 to 8, wherein the biosample is a blood sample and the blood sample is collected, shipped, and/or stored in a tube that has cell- and DNA-stabilizing properties prior to processing the blood sample into plasma.

Claim 22. The method of claim 1 to 8, wherein the biosample is a blood sample and the blood sample is:

not exposed to EDTA prior to processing the blood sample into plasma;

processed into plasma within about 24 to about 72 hours of the blood draw;

maintained, stored, and/or shipped at room temperature prior to processing into plasma; and/or

maintained, stored, and/or shipped without exposure to chilling or freezing prior to processing into plasma.

Claim 23. The method of any one of claims 1 to 8, wherein the plurality of C-RNA molecules further comprises corticotropin releasing hormone (CRH), fibronectin 1 (FN1), pappalysin 2 (PAPPA2), TIMP metallopeptidase inhibitor 3 (TIMP3), leptin (LEP), H19 imprinted maternally expressed transcript (H19), proteoglycan 2, pro eosinophil major basic protein (PRG2), nestin (NES), V-set and immunoglobulin domain containing 4 (VSIG4), and/or Epstein-Barr virus induced 3 (EB13).

Claim 24. The circulating RNA (C-RNA) signature for an increased risk of preeclampsia of any one of claims 9 to 17, wherein the C-RNA signature further comprises CRH, FN1, PAPPA2, TIMP3, LEP, H19, PRG2, NES, VSIG4, and/or EB13.

Claim 25. The method of claim 23, wherein the identification of a plurality of C-RNA molecules consisting of:

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, leptin (LEP), pappalysin 2 (PAPPA2), and V-set and immunoglobulin domain containing 4 (VSIG4);

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, and VSIG4;

ADAMTS2, ARHGEF25, arrestin domain containing 4 (ARRDC4), CLEC4C, LEP, nestin (NES), SKIL, and VSIG4;

ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, corticotropin releasing hormone (CRH), LEP, PAPPA2, SKIL, and VSIG4;

ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or

ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL

is indicative of preeclampsia and/or an increased risk for preeclampsia in the pregnant women.